Galmed Pharmaceuticals Ltd. Board of Directors

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Mr. Allen Baharaff

Mr. Allen Baharaff

Co-Founder, President, CEO & Chairman

Dr. Tali Gorfine

Dr. Tali Gorfine

Medical Consultant

Mr. Yohai Stenzler CPA

Mr. Yohai Stenzler CPA

Chief Accounting Officer

Mr. Doron Cohen

Mr. Doron Cohen

Chief Financial Officer

Mr. Guy Nehemya

Mr. Guy Nehemya

COO & Data Protection Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.